{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:24:20Z","timestamp":1790429060653,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T00:00:00Z","timestamp":1510272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A16892"],"award-info":[{"award-number":["A16892"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/K000128\/1"],"award-info":[{"award-number":["EP\/K000128\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2018,2,15]]},"abstract":"<jats:p>Women vaccinated against HPV16\/18 are approaching the age for cervical screening; however, an updated screening algorithm has not been agreed. We use a microsimulation model calibrated to real published data to determine the appropriate screening intensity for vaccinated women. Natural histories in the absence of vaccination were simulated for 300,000 women using 10,000 sets of transition probabilities. Vaccination with (<jats:italic>i<\/jats:italic>) 100% efficacy against HPV16\/18, (<jats:italic>ii<\/jats:italic>) 15% cross\u2010protection, (<jats:italic>iii<\/jats:italic>) 22% cross\u2010protection, (<jats:italic>iv<\/jats:italic>) waning vaccine efficacy and (<jats:italic>v<\/jats:italic>) 100% efficacy against HPV16\/18\/31\/33\/45\/52\/58 was added, as were a range of screening scenarios appropriate to the UK. To benchmark cost\u2010benefits of screening for vaccinated women, we evaluated the proportion of cancers prevented per additional screen (incremental benefit) of current cytology and likely HPV screening scenarios in unvaccinated women. Slightly more cancers are prevented through vaccination with no screening (70.3%, 95% CR: 65.1\u201375.5) than realistic compliance to the current UK screening programme in the absence of vaccination (64.3%, 95% CR: 61.3\u201366.8). In unvaccinated women, when switching to HPV primary testing, there is no loss in effectiveness when doubling the screening interval. Benchmarking supports screening scenarios with incremental benefits of \u22652.0%, and rejects scenarios with incremental benefits \u22640.9%. In HPV16\/18\u2010vaccinated women, the incremental benefit of offering a third lifetime screen was at most 3.3% (95% CR: 2.2\u20134.5), with an incremental benefit of 1.3% (\u22120.3\u20132.8) for a fourth screen. For HPV16\/18\/31\/33\/45\/52\/58\u2010vaccinated women, two lifetime screens are supported. It is important to know women's vaccination status; in these simulations, HPV16\/18\u2010vaccinated women require three lifetime screens, HPV16\/18\/31\/33\/45\/52\/58\u2010vaccinated women require two lifetime screens, yet unvaccinated women require seven lifetime screens.<\/jats:p>","DOI":"10.1002\/ijc.31094","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T08:02:44Z","timestamp":1507708964000},"page":"709-718","source":"Crossref","is-referenced-by-count":64,"title":["What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study"],"prefix":"10.1002","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4042-4820","authenticated-orcid":false,"given":"Rebecca","family":"Landy","sequence":"first","affiliation":[{"name":"Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine Queen Mary University of London, Charterhouse Square London EC1M 6BQ UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Windridge","sequence":"additional","affiliation":[{"name":"Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine Queen Mary University of London, Charterhouse Square London EC1M 6BQ UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Gillman","sequence":"additional","affiliation":[{"name":"Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine Queen Mary University of London, Charterhouse Square London EC1M 6BQ UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Sasieni","sequence":"additional","affiliation":[{"name":"Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine Queen Mary University of London, Charterhouse Square London EC1M 6BQ UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.026"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62218-7"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21955"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21139"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv316"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.6.506"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.55.4.244"},{"key":"e_1_2_8_9_1","unstructured":"Office for National Statistics.Population Estimates by single year of age and sex for local authorities in the UK mid\u201020152016[cited 9th September 2016]. Available fromhttps:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesf orukenglandandwalesscotlandandnorthernireland."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta13510"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11334"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22527"},{"key":"e_1_2_8_13_1","volume-title":"Cancer incidence in five continents, volume IV","author":"International Agency for Research on Cancer","year":"1982"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600688"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-7-38"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/597307"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70287-X"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29532"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70103-7"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23922"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.290"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29381"},{"key":"e_1_2_8_23_1","unstructured":"Australian Government: Department of Health.National Cervical Screening Programme: Future changes to cervical screening2017[cited 2017 24th May]. Available from:http:\/\/www.cancerscreening.gov.au\/internet\/screening\/publishing.nsf\/content\/future-changes-cervical."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw216"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.6.781"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145548"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30392"},{"key":"e_1_2_8_28_1","unstructured":"NHS England (prepared by PHE).NHS public health functions agreement 2016\u201017: Service specification No.11 Human papillomavirus (HPV) programme.2016."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-172"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181996ffa"},{"key":"e_1_2_8_31_1","unstructured":"MossS GibneyA.HPV primary screening pilots: evaluation report to the national screening committee. February2015. Queen Mary University of London 2015 Available from:https:\/\/legacyscreening.phe.org.uk\/policydb_download.php?doc=560"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.31094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.31094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:09:35Z","timestamp":1695575375000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.31094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,2,15]]}},"alternative-id":["10.1002\/ijc.31094"],"URL":"https:\/\/doi.org\/10.1002\/ijc.31094","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,10]]}}}